L. Roulin
Paris 12 Val de Marne University
22 Papers
26 Citations
L. Roulin is an academic researcher from Paris 12 Val de Marne University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 6 publications.
Chat about Author
Papers
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Emmanuel Bachy,Steven Le Gouill,Roberta Di Blasi,Pierre Sesques,Guillaume Manson,Guillaume Cartron,D. Beauvais,L. Roulin,François-Xavier Gros,Marie-Thérèse Rubio,Pierre Bories,Jacques-Olivier Bay,Cristina Castilla Llorente,Sylvain Choquet,Rene-Olivier Casasnovas,Mohamad Mohty,Stéphanie Guidez,Magalie Joris,Michael Loschi,Sylvain Carras,Julie Abraham,Adrien Chauchet,Laurianne Drieu La Rochelle,Bénédicte Deau-Fischer,Olivier Hermine,Thomas Gastinne,Jean-Jacques Tudesq,E Gat,Florence Broussais,Catherine Thieblemont,Roch Houot,Franck Morschhauser +31 more
TL;DR: In this article , axicabtagene ciloleucel and tisagenlecleucel (tisa-cel) were compared in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL).
High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Laetitia Vercellino,Anne-Ségolène Cottereau,Olivier Casasnovas,Hervé Tilly,Pierre Feugier,Loïc Chartier,Christophe Fruchart,L. Roulin,Lucie Oberic,Gian Matteo Pica,Vincent Ribrag,Julie Abraham,Marc Simon,Hugo Gonzalez,Reda Bouabdallah,Olivier Fitoussi,Catherine Sebban,Armando López-Guillermo,Laurence Sanhes,Franck Morschhauser,Judith Trotman,Bernadette Corront,Bachra Choufi,Sylvia Snauwaert,Pascal Godmer,Josette Brière,Gilles Salles,Philippe Gaulard,Michel Meignan,Catherine Thieblemont +29 more
TL;DR: Even in responding patients, after R-CHOP, high baseline TMTV was a strong prognosticator of inferior PFS and OS, and TMTV combined with ECOG PS may identify an ultra-risk DLBCL population.
145
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
Catherine Thieblemont,Susannah Howlett,René-Olivier Casasnovas,Nicolas Mounier,Aurore Perrot,Franck Morschhauser,Christophe Fruchart,Nicolas Daguindau,Koen Van Eygen,Lucie Oberic,Reda Bouabdallah,Gian Matteo Pica,Emmanuelle Nicolas‐Virezelier,Julie Abraham,Olivier Fitoussi,Sylvia Snauwaert,Jean-Claude Eisenmann,Pauline Lionne-Huyghe,Dominique Bron,Sabine Tricot,Dries Deeren,Hugo Gonzalez,Régis Costello,Katell Le Du,Maria Gomes da Silva,Sebastian Grosicki,Judith Trotman,John Catalano,Dolores Caballero,Richard Greil,Amos Cohen,Philippe Gaulard,L. Roulin,Kenichi Takeshita,Marie-Laure Casadebaig,Hervé Tilly,Bertrand Coiffier +36 more
TL;DR: Lenalidomide maintenance and treatment‐emergent adverse events (TEAEs) on health‐related quality of life (HRQOL) did not negatively impact HRQOL in patients with DLBCL despite TEAEs being more common, when compared with placebo.
18
Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
Simon B. Gressens,Slim Fourati,Anne Le Bouter,Fabien Le Bras,Jehan Dupuis,Mohammad Hammoud,T. El Gnaoui,Romain Gounot,L. Roulin,Karim Belhadj,Corinne Haioun,Sebastien Gallien,Giovanna Melica,François A. Lemonnier +13 more
TL;DR: In this paper , a single-centre study, evaluating the serological responses of mRNA vaccination amongst a cohort of 200 patients affected by lymphoid malignancies after two or three doses using an industrial SARS-CoV-2 serology assay for anti-receptor binding domain (RBD) Spike IgG detection and quantification.
11
Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis.
Fabien Le Bras,Jehan Dupuis,François Lemonnier,Silvia Oghina,Diane Bodez,Amandine Ladaique,Alizee Maarek,L. Roulin,Asma Beldi Ferichou,Valérie Frenkel,Corinne Haioun,Thibaud Damy,Karim Belhadj +12 more
TL;DR: Venetoclax is an orally bioavailable small molecule inhibitor of the anti-apoptotic protein BCL-2 and has been shown to have efficacy against myeloma (MM), particularly in p...
10